Dr. Ralph DeFronzo, a Key Opinion Leader in diabetes care, discusses the future of Menin Inhibitors, specifically icovamenib, and its clinical results at WCIRDC 2025. Biomea Fusion, Inc. released an interview featuring Dr. DeFronzo, highlighting the potential of icovamenib in treating diabetes. Dr. DeFronzo also presented at the conference, discussing the impact of Menin Inhibitors and insulin sensitizers. Icovamenib is an investigational inhibitor of menin, aiming to restore beta cell function in patients with diabetes, particularly those with severe insulin deficiency. The webinar series, astr<60, focuses on emerging therapies and insights in biotechnology and capital markets. Biomea Fusion is a clinical-stage biopharmaceutical company working on oral small molecule therapies for diabetes and obesity, with a mission to deliver transformative treatments for patients.
Read more at GlobeNewswire: Biomea Fusion Announces KOL Presentation and Interview on